Amylyx Pharmaceuticals Inc. (AMLX) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Amylyx Pharmaceuticals Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$28.07
−0.81% today
Market cap
$3.6B
Overall quality
51/100
Kronos AI 30-day
−5.9%
3 of 8 simulated paths end higher
Amylyx Pharmaceuticals Inc. (AMLX) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $3.6B. It trades at $28.07, down 0.81% today. Its overall quality score is 51 out of 100, ranked against the whole US market. 9 analysts' average target of $46.63 implies +66.1% from today's price. Kronos AI's 30-day forecast is −5.9% (3 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $46.63 |
| Low – high | $39.00 – $57.00 |
| Analysts | 9 |
| Upside to average | +66.1% |
Kronos AI 30-day forecast
| Expected close | $26.64 (−5.9%) |
| Likely range | −27.8% … +2.0% |
| As of | 2026-10-27 |
3 of 8 simulated paths end higher.
Quality scores
| Profitability | 39 |
| Solvency | 52 |
| Growth | 62 |
| Overall | 51 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.